Novel methodology for labelling mesoporous silica nanoparticles using the 18F isotope and their in vivo biodistribution by positron emission tomography
Source abstract
Abstract
Nanoparticles have been proposed for several biomedical applications due to their potential as drug carriers, diagnostic and therapeutic agents. However, only a few of them have been approved for their use in humans. In order to gauge the potential applicability of a specific type of nanoparticle, in vivo biodistribution studies to characterize their pharmacokinetic properties are essential. In this regard, mesoporous silica nanoparticles (30-130 nm) have been functionalized with amino groups in order to react with N-succinimidyl 4-[F-18]fluorobenzoate and thus anchor the F-18 positron emission isotope by using a novel and easy labelling strategy. In vivo biodistribution was characterized in mice after intravenous administration of radiolabelled nanoparticles by positron emission tomography. Our results indicated that radiolabelled mesoporous silica nanoparticles were excreted into bile and urine and accumulated mainly in the organs of the reticuloendothelial system and lungs.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Radiopharmaceutical Chemistry and Applications · Lanthanide and Transition Metal Complexes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Asefa T, Tao Z (2012) Biocompatibility of mesoporous silica nanoparticles. Chem Res Toxicol 25:2265–228410.1021/tx300166u ↗
2. Bitar A, Ahmad NM, Fessi H, Elaissari A (2012) Silica-based nanoparticles for biomedical applications. Drug Discov Today 17:1147–115410.1016/j.drudis.2012.06.014 ↗
3. Borchardt G, Brandriss S, Kreuter J, Margel S (1994) Body distribution of 75Se-radiolabeled silica nanoparticles covalently coated with omega-functionalized surfactants after intravenous injection in rats. J Drug Target 2:61–7710.3109/10611869409015894 ↗
4. Botella P, Abasolo I, Fernandez Y, Muniesa C, Miranda S, Quesada M, Ruiz J, Schwartz S, Corma A (2011) Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. J Control Release 156:246–25710.1016/j.jconrel.2011.06.039 ↗
5. Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R, Theuer CP, Barnhart TE, Cai W (2014) Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep 4:508010.1038/srep05080 ↗
6. Crommelin DJA, Florence AT (2013) Towards more effective advanced drug delivery systems. Int J Pharm 454:496–51110.1016/j.ijpharm.2013.02.020 ↗
7. Duan X, Li Y (2013) Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 9:1521–153210.1002/smll.201201390 ↗
8. Etgar L, Schuchardt G, Costenaro D, Carniato F, Bisio C, Zakeeruddin SM, Nazeeruddin MK, Marchese L, Graetzel M (2013) Enhancing the open circuit voltage of dye sensitized solar cells by surface engineering of silica particles in a gel electrolyte. J Mater Chem A 1:10142–1014710.1039/c3ta11436h ↗
9. Guadagnini R, Moreau K, Hussain S, Marano F, Boland S (2013) Toxicity evaluation of engineered nanoparticles for medical applications using pulmonary epithelial cells. Nanotoxicology. doi: 10.3109/17435390.2013.855830
10. Guerrero S, Herance JR, Rojas S, Mena JF, Gispert JD, Acosta GA, Albericio F, Kogan MJ (2012) Synthesis and in vivo evaluation of the biodistribution of a 18F-labeled conjugate gold-nanoparticle-peptide with potential biomedical application. Bioconjug Chem 23:399–40810.1021/bc200362a ↗
11. Huang X, Li L, Liu T, Hao N, Liu H, Chen D, Tang F (2011) The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 5:5390–539910.1021/nn200365a ↗
12. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA (2007) Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 13:636–64110.1038/nm1571 ↗
13. Karmani L, Labar D, Valembois V, Bouchat V, Nagaswaran PG, Bol A, Gillart J, Leveque P, Bouzin C, Bonifazi D, Michiels C, Feron O, Gregoire V, Lucas S, Van der Borght T, Gallez B (2013) Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Contrast Media Mol Imaging 8:402–40810.1002/cmmi.1539 ↗
14. Kim BY, Rutka JT, Chan WC (2010) Nanomedicine. N Engl J Med 363:2434–244310.1056/NEJMra0912273 ↗
15. Kumar R, Roy I, Ohulchanskky TY, Vathy LA, Bergey EJ, Sajjad M, Prasad PN (2010) In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano 4:699–70810.1021/nn901146y ↗
16. Lavik E, von Recum H (2011) The role of nanomaterials in translational medicine. ACS Nano 5:3419–342410.1021/nn201371a ↗
17. Lee SB, Kim HL, Jeong HJ, Lim ST, Sohn MH, Kim DW (2013) Mesoporous silica nanoparticle pretargeting for PET imaging based on a rapid bioorthogonal reaction in a living body. Angew Chem Int Ed Engl 52:10549–1055210.1002/anie.201304026 ↗
18. Lu J, Liong M, Li Z, Zink JI, Tamanoi F (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6:1794–180510.1002/smll.201000538 ↗
19. Mading P, Fuchtner F, Wust F (2005) Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB). Appl Radiat Isot 63:329–33210.1016/j.apradiso.2005.03.005 ↗
20. Malfatti MA, Palko HA, Kuhn EA, Turteltaub KW (2012) Determining the pharmacokinetics and long-term biodistribution of SiO2 nanoparticles in vivo using accelerator mass spectrometry. Nano Lett 12:5532–553810.1021/nl302412f ↗
21. Martin R, Alvaro M, Herance JR, Garcia H (2010a) Fenton-treated functionalized diamond nanoparticles as gene delivery system. ACS Nano 4:65–7410.1021/nn901616c ↗
22. Martin R, Menchon C, Apostolova N, Victor VM, Alvaro M, Herance JR, Garcia H (2010b) Nano-jewels in biology. Gold and platinum on diamond nanoparticles as antioxidant systems against cellular oxidative stress. ACS Nano 4:6957–696510.1021/nn1019412 ↗
23. Menchon C, Martin R, Apostolova N, Victor VM, Alvaro M, Herance JR, Garcia H (2012) Gold nanoparticles supported on nanoparticulate ceria as a powerful agent against intracellular oxidative stress. Small 8:1895–190310.1002/smll.201102255 ↗
24. Meng H, Xue M, Xia T, Ji Z, Tarn DY, Zink JI, Nel AE (2011) Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 5:4131–414410.1021/nn200809t ↗
25. Miller L, Winter G, Baur B, Witulla B, Solbach C, Reske S, Linden M (2014) Synthesis, characterization, and biodistribution of multiple (89)Zr-labeled pore-expanded mesoporous silica nanoparticles for PET. Nanoscale 6:4928–493510.1039/C3NR06800E ↗
26. Moros M, Mitchell SG, Grazu V, de la Fuente JM (2013) The fate of nanocarriers as nanomedicines in vivo: important considerations and biological barriers to overcome. Curr Med Chem 20:2759–277810.2174/0929867311320220003 ↗
27. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P (2013) Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev 42:1147–123510.1039/C2CS35265F ↗
28. Rojas S, Gispert JD, Martin R, Abad S, Menchon C, Pareto D, Victor VM, Alvaro M, Garcia H, Herance JR (2011) Biodistribution of amino-functionalized diamond nanoparticles. In vivo studies based on 18F radionuclide emission. ACS Nano 5:5552–555910.1021/nn200986z ↗
29. Rojas S, Gispert JD, Abad S, Buaki-Sogo M, Victor VM, Garcia H, Herance JR (2012) In vivo biodistribution of amino-functionalized ceria nanoparticles in rats using positron emission tomography. Mol Pharm 9:3543–355010.1021/mp300382n ↗
30. Sakai N, Takakura M, Imamura H, Sugimoto M, Matsui Y, Miyoshi H, Nakayama A, Yoneda M (2012) Whole-body distribution of 14C-labeled silica nanoparticles and submicron particles after intravenous injection into Mice. J Nanopart Res 14:1–1110.1007/s11051-012-0849-x ↗
31. Sarparanta M, Makila E, Heikkila T, Salonen J, Kukk E, Lehto VP, Santos HA, Hirvonen J, Airaksinen AJ (2011) (18)F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. Mol Pharm 8:1799–180610.1021/mp2001654 ↗
32. Tan W, Wang K, He X, Zhao XJ, Drake T, Wang L, Bagwe RP (2004) Bionanotechnology based on silica nanoparticles. Med Res Rev 24:621–63810.1002/med.20003 ↗
33. Uboldi C, Giudetti G, Broggi F, Gilliland D, Ponti J, Rossi F (2012) Amorphous silica nanoparticles do not induce cytotoxicity, cell transformation or genotoxicity in Balb/3T3 mouse fibroblasts. Mutat Res 745:11–2010.1016/j.mrgentox.2011.10.010 ↗
34. Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, Che E, Hu L, Zhang Q, Jiang T, Wang S (2014) Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine. doi: 10.1016/j.nano.2014.09.014
35. Wu SH, Mou CY, Lin HP (2013) Synthesis of mesoporous silica nanoparticles. Chem Soc Rev 42:3862–387510.1039/c3cs35405a ↗
36. Xie G, Sun J, Zhong G, Shi L, Zhang D (2010) Biodistribution and toxicity of intravenously administered silica nanoparticles in mice. Arch Toxicol 84:183–19010.1007/s00204-009-0488-x ↗